Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration
The VEGF-A121 isoform has been uniquely demonstrated as a clear marker of bevacizumab therapy in both plasma and serum, motivating further research on pursuing these isoforms as biomarkers in cancer care.
Authors
- Munekazu Yamakuchi (ORCID: https://orcid.org/0000-0003-2181-7194)
- Junichi Nakazawa
- Chieko Fujisaki
- Bibek Aryal (ORCID: https://orcid.org/0000-0003-0257-7439)
- Kazunori Takenouchi (ORCID: https://orcid.org/0000-0003-1946-457X)
- Drew N. Maywar (ORCID: https://orcid.org/0000-0002-2674-0520)
- Yoko Oyama
- Akito Tabaru (ORCID: https://orcid.org/0000-0001-6018-9974)
- Teruto Hashiguchi (ORCID: https://orcid.org/0000-0003-4820-8268)
- Yutaka Imoto (ORCID: https://orcid.org/0000-0002-6094-456X)
- Kazuhiko Higurashi
- Masashi Okawa (ORCID: https://orcid.org/0000-0001-7618-2240)
- Sadayuki Higashi
- Yoshiharu Soga (ORCID: https://orcid.org/0000-0001-6718-6960)
- Kiyonori Tanoue (ORCID: https://orcid.org/0000-0002-9128-2298)
- Keiichi Inoue (ORCID: https://orcid.org/0000-0002-6898-4347)
- Shuji Tachioka
- Shingo Yamada (ORCID: https://orcid.org/0000-0001-9488-668X)
- Hideaki Kanda
- Masahiro Kawahira (ORCID: https://orcid.org/0000-0003-3660-8280)
- T Kodama
- Hirohito Hashinokuchi
Institutions
- Kagoshima University (JP)
- Rochester Institute of Technology (US)
- Kagoshima University Hospital (JP)
- Kagoshima City Hospital (JP)
- Shino-Test Corporation
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1371/journal.pone.0316035
- Citations
- 2
- Primary Topic
- Angiogenesis and VEGF in Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.47